Table 4.
Percentage of patients reaching efficacy end‐points, by study phase and treatment group, using data obtained after dose adjustment
| Treatment group | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall phase (0–120 h) | Acute phase (0–24 h) | Delayed phase (24–120 h) | |||||||
| End‐point | A 125/80 | A 40/25 | ST | A 125/80 | A 40/25 | ST | A 125/80 | A 40/25 | ST |
| Total no. | 146 | 143 | 149 | 146 | 143 | 150 | 146 | 143 | 149 |
| No emesis (%) | 76.7* | 74.1* | 51.0 | 89.7 | 90.2 | 83.3 | 78.8* | 77.6* | 53.0 |
| No rescue (%) | 80.8 | 80.4 | 79.2 | 95.2 | 98.6 | 96.0 | 82.2 | 81.1 | 79.9 |
| No nausea (%) | 34.2 | 28.0 | 24.2 | 67.1 | 63.6 | 66.0 | 34.9 | 30.1 | 26.2 |
| No significant nausea (%) | 69.2 | 60.8 | 55.7 | 90.4 | 84.6 | 88.0 | 72.6** | 60.8 | 56.4 |
| Complete protection (%) | 61.6** | 53.1 | 43.0 | 83.6 | 80.4 | 82.0 | 65.1** | 55.2 | 44.3 |
| Total control (%) | 33.6 | 28.0 | 24.2 | 66.4 | 63.6 | 64.7 | 34.2 | 30.1 | 26.2 |
*P < 0.001. **P < 0.01. A 125/80: standard therapy plus aprepitant 125 mg on day 1 and aprepitant 80 mg on days 2–5; A 40/25: standard therapy plus aprepitant 40 mg on day 1 and 25 mg on days 2–5; No nausea: nausea score 0; No significant nausea: nausea score 0 and 1; Complete protection: no emesis, no rescue therapy and no significant nausea (nausea score 0 and 1); Total control: no emesis, no rescue therapy and no nausea (nausea score 0). ST, standard therapy.